Biomarker · Hormone receptor

Progesterone receptor (PR)

Progesterone receptor protein expression measured by immunohistochemistry on tumor tissue; used together with ER as a predictive and prognostic marker in breast cancer.

CI-BIO-00000003PGR graph →NCIt C15496

Also calledPR · PgR · PR-positive · PGR expression

Derived

Associated cancers (1)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Breast Neoplasm	4	2	2	—	0 / 4 / 0 / 0 / 0

Derived

Drugs with predictive evidence (2)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
TamoxifenSmall Molecule	2	2	—	B	—	Malignant Breast Neoplasm
ExemestaneSmall Molecule	1	1	—	B	—	Malignant Breast Neoplasm

Curated items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (2)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PGR Expression2
Tamoxifen

Regulatory

Approvals mentioning the linked drugs (42)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

health-canada-dpdRegulatory

Clinical trials

Active trials (33)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 15 recruiting · 15 active phase 3 · 282 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 1–33 of 33 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05161195	Roll-over Study to Allow Continued Access to Ribociclib	active not recruiting	Phase 4	134	Novartis Pharmaceuticals

Literature

Linked publications (3)

Publications linked to the scope gene(s) through PubMed entity edges; 25 per page, newest first.

pubmedPublishedShowing 1–3 of 3 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.
· J Clin Oncol · 2011 · PMID 21422407 · validated civic_curation pubmed
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
· Ann Oncol · 2006 · PMID 16497822 · validated civic_curation pubmed
Biomarkers for the clinical management of breast cancer: international perspective.
· Int J Cancer · 2013 · PMID 23280579 · validated civic_curation pubmed

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Exemestane	CA Health Canada	—	Marketed in Canada as APO-EXEMESTANE (DIN 02419726) under ATC L02BG06 EXEMESTANE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Aug 4, 2017	May 1, 2014	health-canada-dpd
Exemestane	CA Health Canada	—	Marketed in Canada as MED-EXEMESTANE (DIN 02407841) under ATC L02BG06 EXEMESTANE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 2, 2013	health-canada-dpd
Exemestane	CA Health Canada	—	Marketed in Canada as TEVA-EXEMESTANE (DIN 02408473) under ATC L02BG06 EXEMESTANE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jan 17, 2025	Oct 1, 2013	health-canada-dpd
Exemestane	CA Health Canada	—	Marketed in Canada as ACT EXEMESTANE (DIN 02390183) under ATC L02BG06 EXEMESTANE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 26, 2012	health-canada-dpd
Exemestane	CA Health Canada	—	Marketed in Canada as AROMASIN (DIN 02242705) under ATC L02BG06 EXEMESTANE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 17, 2000	health-canada-dpd
Exemestane	CA Health Canada	—	Marketed in Canada as GD-EXEMESTANE (DIN 02359693) under ATC L02BG06 EXEMESTANE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Oct 29, 2020	—	health-canada-dpd
Exemestane	CA Health Canada	—	Marketed in Canada as MYLAN-EXEMESTANE (DIN 02405075) under ATC L02BG06 EXEMESTANE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Nov 2, 2016	—	health-canada-dpd
Exemestane	US FDA	—	Efficacy supplement 2016-07-25 (see label)	approved	Jul 25, 2016	openfda
Exemestane	US FDA	—	Efficacy supplement 2005-10-05 (see label)	approved	Oct 5, 2005	openfda
Exemestane	US FDA	Malignant Breast Neoplasm	adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to EXEMESTANE for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ).	approved	Oct 21, 1999	openfda
Exemestane	US FDA	Malignant Breast Neoplasm	treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ).	approved	Oct 21, 1999	openfda
Tamoxifen	CA Health Canada	—	Marketed in Canada as TAMOXIFENE - 20 (DIN 02296748) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 27, 2011	Oct 29, 2007	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as TAMOXIFENE - 10 (DIN 02296721) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 27, 2011	Oct 29, 2007	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as TAMOXIFEN (DIN 02237596) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 25, 2016	Sep 28, 1999	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as TAMOXIFEN (DIN 02237597) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 25, 2016	Sep 28, 1999	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as PMS-TAMOXIFEN (DIN 02237460) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 28, 2016	Dec 1, 1998	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as PMS-TAMOXIFEN (DIN 02237459) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 28, 2016	Dec 1, 1998	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as TAMONE - (20 MG) (DIN 02063751) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 2, 2007	Dec 31, 1996	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as TAMONE - (10 MG) (DIN 02063778) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 2, 2007	Dec 31, 1996	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as NOLVADEX-D TAB 20MG (DIN 02048485) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Mar 22, 2023	Dec 31, 1995	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as MYLAN-TAMOXIFEN (DIN 02088428) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jan 9, 2017	Dec 31, 1994	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as NOLVADEX TAB 10MG (DIN 02048477) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Apr 1, 2003	Dec 31, 1994	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as MYLAN-TAMOXIFEN (DIN 02089858) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jan 9, 2017	Dec 31, 1994	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as TAMOPLEX TAB 20MG (DIN 01951947) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 9, 1996	Dec 31, 1992	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as TAMOPLEX TAB 10MG (DIN 01951939) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 9, 1996	Dec 31, 1992	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as TEVA-TAMOXIFEN (DIN 00851965) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1990	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as TEVA-TAMOXIFEN (DIN 00851973) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1990	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as APO-TAMOX TAB 20MG (DIN 00812390) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1989	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as TAMONE TAB 20MG (DIN 00810452) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 10, 1996	Dec 31, 1989	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as APO-TAMOX TAB 10MG (DIN 00812404) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1989	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as TAMONE TAB 10MG (DIN 00810444) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 10, 1996	Dec 31, 1989	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as TAMOFEN 10 (DIN 01926624) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jan 11, 2011	Dec 31, 1986	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as TAMOFEN 20 (DIN 01926632) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jan 14, 2011	Dec 31, 1986	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as PENTA-TAMOXIFEN TABLETS (DIN 02232552) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled (Unreturned Annual)since Apr 5, 2018	—	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as PENTA-TAMOXIFEN TABLETS (DIN 02232551) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled (Unreturned Annual)since Apr 5, 2018	—	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as DOM-TAMOXIFEN (DIN 02237599) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Oct 25, 2016	—	health-canada-dpd
Tamoxifen	CA Health Canada	—	Marketed in Canada as DOM-TAMOXIFEN (DIN 02237598) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 25, 2016	—	health-canada-dpd
Tamoxifen	US FDA	—	Efficacy supplement 2018-09-25 (see label)	approved	Sep 25, 2018	openfda
Tamoxifen	US FDA	Malignant Breast Neoplasm	For treatment of adult patients with estrogen receptor-positive metastatic breast cancer	approved	Oct 29, 2005	openfda
Tamoxifen	US FDA	—	To reduce risk of invasive breast cancer following breast surgery and radiation in adult women with ductal carcinoma in situ (DCIS)	approved	Oct 29, 2005	openfda
Tamoxifen	US FDA	Malignant Breast Neoplasm	To reduce the incidence of breast cancer in adult women at high risk	approved	Oct 29, 2005	openfda
Tamoxifen	US FDA	Malignant Breast Neoplasm	For adjuvant treatment of adult patients with early stage estrogen receptor- positive breast cancer	approved	Oct 29, 2005	openfda

Drug

Jurisdiction · authority

Cancer

Indication

Status

Approval date

Source

Exemestane

CA Health Canada

—

Marketed in Canada as APO-EXEMESTANE (DIN 02419726) under ATC L02BG06 EXEMESTANE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.

withdrawnsource: Dormantsince Aug 4, 2017

May 1, 2014